The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
Open accessAbstract
BACKGROUND: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL Receptor 1 (TRAIL-R1). METHODS: This phase II multicentre study was designed to evaluate the efficacy and safety of mapatumumab in patients with colorectal cancer (CRC) who had failed to respond to, were intolerant to, or not candidates for fluoropyrimidine, oxaliplatin, and irinotecan-based regimens. All patients received two loading doses of mapatumumab (20 mg kg(-1) every 14 days), followed by maintenance therapy with 10 mg kg(-1) infused every 14 days. RESULTS: A total of 38 patients, who had progressive disease after a median of three earlier chemotherapy lines, were enrolled. No response according to the Response Evaluation Criteria in Solid Tumors was observed. A total of 12 patients (32%) achieved stable disease for a median of 2.6 months. The median progression-free survival was 1.2 months. The most common adverse events reported, regardless of relationship, were fatigue, nausea, anorexia, and abdominal pain. Plasma mapatumumab concentrations were within the range of exposures predicted by the results of phase I studies of mapatumumab. CONCLUSION: No clinical activity of single-agent mapatumumab was observed in patients with advanced refractory CRC. However, on the basis of its favourable safety profile and pre-clinical evidence of potential synergy in combination with agents commonly used in the treatment of colorectal cancer, further evaluation of mapatumumab in combination with chemotherapy is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 3×
“Pre-clinical studies have shown that TRAIL and agonistic antibodies directed to TRAIL receptors can induce apoptosis in cancer cell lines and inhibit tumour growth in xenograft models (Pukac et al, 2005; Ashkenazi, 2008; Humphreys and Halpern, 2008; Johnstone et al, 2008).”
BackgroundConnolly, K., Mitter, R., Muir, M., Jodrell, D., & Guichard, S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0872-x · Cited by 34
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Metadata
- Authors
- Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S.
- Venue
- British Journal of Cancer
- Published
- 2010-01-12
- Volume
- 102
- Issue
- 3
- Pages
- 506-512
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2037978214
- Cited by
- 180
- References
- 4
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6605507
- The paper
- Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010). Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.